Moreover, we demonstrated that SLC25A32 activates the PI3K-AKT signaling pathway in GBM cells to maintain malignant phenotype, suggesting that SLC25A32 is a potential therapeutic target in GBM. This evidence concerns the gene AKT1 and glioblastoma.